Biopharma
🇪🇺 EMAEMA news and analysis for pharmaceutical BD, investment, and market access
Global biopharma insights for investors & BD. Track drug development, M&A, and market trends shaping the pharmaceutical landscape.
Showing 1–12 of 17 articles
Quick answer
NovaPharmaNews Biopharma hub for EMA covers 17 published articles — news and analysis for pharma BD, investors, and market access teams. Browse related topics below or explore companies, pipeline, and events linked from each story.
EU Pharma Package exclusivity timelines: what innovators can do now
China Becomes Big Pharma's Essential R&D Partner
Owkin and AstraZeneca Enhance AI Collaboration for Drug Research
European Navenibart Deal: A Strategic Win for BioCryst's Rare Disease Portfolio
Naldemedine Approved in China for Opioid-Induced Constipation: A New Option for Cancer Supportive Care
SERB Pharmaceuticals Acquires European and MENA Rights to Idefirix® (imlifidase) from Hansa Biopharma AB
Viridian Partners with WuXi Bio for Eye Drug Supply Amid FDA Decision
Roche's Licensing Deal for Xofluza: Implications and Insights
Gilead's $140M Deal with Yuhan: Implications for Pharma
BioPharma Clinical Trials EU: Daily Insights
Elanco's Negasunt and Tanidil Receive FDA Emergency Authorization for New World Screwworm Treatment in Livestock
Pharma 2026: Key Takeaways from EU Biopharma & Medtech
Frequently asked questions
How often is this topic updated?
New articles are published continuously as regulatory, clinical, and commercial signals break. Use the content-type filters for latest news vs in-depth analysis.
Where does this coverage come from?
Editorial intelligence combines FDA openFDA, ClinicalTrials.gov, SEC EDGAR, congress calendars, and analyst reporting. See our data sources policy for attribution.